Trial Outcomes & Findings for Dexamethasone and Block Duration in Upper Extremity (NCT NCT01756573)
NCT ID: NCT01756573
Last Updated: 2019-05-14
Results Overview
Recruitment status
TERMINATED
Study phase
NA
Target enrollment
5 participants
Primary outcome timeframe
72 hrs
Results posted on
2019-05-14
Participant Flow
Participant milestones
| Measure |
Bupivacaine
Control
Bupivacaine
|
Bupivacaine With Dexamethasone
Dexamethasone will be mixed with bupivacaine
Dexamthsone
Bupivacaine
|
Intravenous Dexamethasone
Dexamethasone will be given intravenously
Dexamthsone
Bupivacaine
|
|---|---|---|---|
|
Overall Study
STARTED
|
3
|
1
|
1
|
|
Overall Study
COMPLETED
|
3
|
1
|
1
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Dexamethasone and Block Duration in Upper Extremity
Baseline characteristics by cohort
| Measure |
Bupivacaine
n=3 Participants
Control
Bupivacaine
|
Bupivacaine With Dexamethasone
n=1 Participants
Dexamethasone will be mixed with bupivacaine
Dexamthsone
Bupivacaine
|
Intravenous Dexamethasone
n=1 Participants
Dexamethasone will be given intravenously
Dexamthsone
Bupivacaine
|
Total
n=5 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
3 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Sex/Gender, Customized
Female
|
2 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
|
Sex/Gender, Customized
Male
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
|
Region of Enrollment
United States
|
3 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
PRIMARY outcome
Timeframe: 72 hrsPopulation: study terminated prematurely due to lack of resources and participation- no data collected for Outcome measures and no analysis done
Outcome measures
Outcome data not reported
Adverse Events
Bupivacaine
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Bupivacaine With Dexamethasone
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Intravenous Dexamethasone
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place